Ipca Laboratories Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4bzrtv5h2hg1qu7pi5ekyn3c.pdf

Key Takeaways


Margin Walk: What Compressed, What Recovers

Harish Kamath: "Gross margin is not a concern for us. It's a short-term issue."

API Business: The Trough and the Turn

Harish Kamath: "See what has happened, actually, whatever KSM we purchased at higher prices, they got converted into API, which got sold at a lower price. So that was going on for last two to three quarters. Maybe some pain will be there in the fourth quarter. But from the next financial year, first quarter onwards, everything should be back to normal."

Domestic Formulations: Market Share Gains, Chronic Slowdown

Ajit Kumar: "So post-COVID also, that also may be one of the impact could be there in this market, because we have never seen this kind of growth in Cardiovasculars and Antidiabetics for last 15, 20 years. This market has been significantly moving up. It's only the current year that your market itself has not done that well."

Export Formulations and ROW Markets


Dewas Plant: The Zero-Revenue Cost Center

Ajit Kumar: "No, so, current year, even Dewas plant all costs are debited to P&L account, there are no business. It will — all cost only because till the time we start filing and getting approval, depreciations and all your people cost, testing costs, all the energy cost, everything is debited to P&L account, and there are no top line coming from that plant. So it's only validation mode. So it's a one-year 1.5 years, that pain is there in pharma industry everywhere."

Regulatory and Pipeline Updates


Guidance & Commitments

CommitmentSpecificsTimeline
Q4 FY23 revenue growthAlmost around 10% to 12% rangeQ4 FY23
FY24 EBITDA marginAround 21%FY24
Margin trajectory beyond FY24Margins to rise ~1% every year for three years, with no significant field force expansionFY25–FY27
API business full-year FY237–8% nine-month decline to be entirely covered; full year more or less flat vs. last year (~INR 1,311 cr)FY23
API gross margin normalizationEverything back to normal from Q1 FY24 as high-cost KSM inventory clearsQ1 FY24
Export Branded Formulation full-year growthIn excess of 17–18%FY23
ROW market growthContinue to grow around 15–17%Ongoing
Dewas plant filingsFilings to start in early next year (beginning) after validations and six-month stabilityEarly FY25
Overall company growth FY24Almost around 12–13%FY24
API growth FY24Around 10%; faster growth only after Dewas capacities are available and approvedFY24
Promotional spendTo remain at the same absolute level next year, creating operating leverage as revenue growsFY24
CapexINR 400–500 crores total, including routine maintenance capex (depreciation ~INR 200 cr)FY24–25
Biotech plant commissioningTo be commissioned next year; ~INR 150 cr investmentFY24
NLEM price increase12% WPI-based price increase effective 1 April; net NLEM impact ~3–3.5% after increaseApril 2023
Tax rateLikely in the range of 29–30%Ongoing

Key Metrics

MetricQ3 FY23
Revenue₹702 cr (Domestic Formulation), +9% YoY from ₹645 cr
Domestic Formulation 9M growth~10%
Export Branded Formulation revenue₹125 cr, +17% YoY from ₹109 cr
Export Branded Formulation 9M growth~11%
Generic export growth (incl. Institutions)14%
Generic export growth (excl. Institutions)~6%
API revenue₹322 cr, +4% YoY from ₹310 cr
API 9M decline~7%, from ₹1,084 cr to ~₹1,004 cr
Material cost to total income ratio34.13%, vs 32.46% in Q3 FY22, +1.67 ppt
9M material cost ratio~33.88%, marginally higher than 33% in FY22
Forex loss (other expenses)~₹16 cr loss, vs ~₹10 cr gain in Q3 FY22
EBITDA margin guidance (FY24)~21%
NLEM price reduction impact (annual)~₹70 cr reduction
NLEM contribution to domestic business17% as of January-end
Scheduled Formulation price reduction~15%
Wholesale price increase expected (April)~12%
Net NLEM impact for FY24~3% to 3.5% reduction
MR additions in current year~1,500
Promotional cost increase (9M)~40% to 45% vs last year
Energy cost increase (current year)~45%
Travel cost increase~doubled
Manpower cost increase (reported)13%, excluding incentive is higher
Domestic market share (IQVIA, 2022)1.86%, up from 1.77% in 2021
IQVIA rank17th company, up from 21st
Acute therapies rank13th, three-rank gain
Chronic segment rank18th, one-rank gain
Rheumatoid Arthritis & Osteoarthritis growth15%
Cardiovascular & Anti-diabetics growth~2%
Antimalarials decline (quarter)~36%
Antimalarials decline (9M)~37%
CNS business growth~18%
Derma growth~18%
Ophthalmology portfolio growth~17%
Neuro growth~13%
Cough and Cold growth~10%
Antibacterials 9M revenue₹134 cr, vs ₹143 cr in FY22
ROW market business (full year)Crossing ₹500 cr for the first time
ROW market growth expectation~15% to 17%
API business FY24 growth expectation~10%
Overall company FY24 growth expectation~12% to 13%
Tax rate expectation~29% to 30%
Capex guidance (FY24–25, per year)₹400 cr to ₹500 cr, incl. maintenance
Biotech project capex~₹150 cr, commissioning next year
Biotech R&D spend (current year)~₹20 cr to ₹25 cr
Onyx UK expected revenue (current year)~GBP 1.4 cr to 1.5 cr, ~27% margin
European business growth (current year)~20%
FY23 YTD net forex loss~₹41.9 cr
Artemisinin price history range$140 to $800